HIV protease inhibitors: Present and future

Cecilia Pizzocolo, Antonella Castagna, Adriano Lazzarin

Research output: Contribution to journalArticlepeer-review


Antiretroviral therapy offers many options, largely based on the next-generation protease inhibitors (PIs). Early PI-based treatments involve high pill burdens and dosing schedules, and concerns of long-term toxicities are well established. In patients who have already achieved viral suppression, novel agents and strategies should be used to simplify the dosing treatment, reduce adverse events or preserve drug options. In experienced patients, drug escalation between PIs and different associations between classes allow virological suppression to be reached in the majority of patients. Therefore, there is a persistent clinical need for the discovery and development of new protease inhibitors. Several firms are trying to develop new types of PIs that will not be cross-resistant with existing drugs and will not require ritonavir boosting. This article aims to offer an overview on present drug options recommended for treatment in naive and experienced patients, new strategies currently undergoing clinical evaluation and new compounds in the pipeline.

Original languageEnglish
Pages (from-to)571-580
Number of pages10
JournalFuture Virology
Issue number5
Publication statusPublished - May 2011


  • atazanavir
  • darunavir
  • drug development
  • HIV protease inhibitor
  • HIV protease inhibitors pipeline
  • lopinavir
  • NRTI-sparing regimen
  • protease inhibitors monotherapy
  • unboosted protease inhibitor

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'HIV protease inhibitors: Present and future'. Together they form a unique fingerprint.

Cite this